Don't Be Surprised to Dispense Baricitinib for COVID-19

January 2021

The oral rheumatoid arthritis med baricitinib (Olumiant) is now authorized to treat COVID-19 in hospitalized patients.

Baricitinib is a Janus kinase (JAK) inhibitor that helps reduce inflammation...and it may have antiviral effects.

Adding it to remdesivir (Veklury) for certain COVID-19 patients may reduce recovery time by one day...compared to remdesivir alone.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Familiarize Yourself With the First COVID-19 Vaccines
Pediatrics Help Keep Pediatric Patients Safe From Med Errors
COVID-19 Avoid Errors With the New Monoclonal Antibodies for COVID-19
IV Medications Stay Alert for Premixes That Should NOT Be Used in Pregnancy
Infectious Diseases Don't Be Surprised to Dispense Baricitinib for COVID-19
Med Safety Be Aware That Bar-Code Scanning Is NOT Foolproof
Allergic Reactions Palforzia Will Be a New Treatment for Peanut Allergy
New Drugs Think of IV Oliceridine as Similar to IV Morphine
Obesity & Weight Loss Plenity Will Be a New Medical Device for Weight Loss